Idera Pharmaceuticals, Inc. is providing an update on its tilsotolimod clinical development program. ILLUMINATE 301 – Randomized phase 3 trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory metastatic melanoma: approximately 100 sites active in 11 countries; Planned enrollment target of 454 patients; As of January 13, 2020, 427 patients enrolled, representing 94% enrollment; ILLUMINATE 206 – Phase 2, open-label, multi-cohort, multi-center study to test the safety and effectiveness of tilsotolimod in combination with ipilimumab and nivolumab for the treatment of solid tumors: trial initiated on September 30, 2019, leading with the MSS-CRC cohort; Initial safety run-in cohort of 10 patients with MSS-CRC fully enrolled; and Preliminary objective response rate (ORR) and safety data from this cohort expected in second quarter of 2020. ILLUMINATE 204 – Phase 1/2 trial of tilsotolimod in combination with ipilimumab or pembrolizumab in patients with anti-PD-1 refractory metastatic melanoma: Completed enrollment with 52 patients (49 evaluable) at tilsotolimod 8 mg with ipilimumab in February 2019; and Final results from the ILLUMINATE 204 trial are expected to be released in second quarter of 2020; and Data to be presented include ORR, median OS, duration of response (DOR) and safety.